Peipei Song

Dr. Peipei Song


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2025 in Intractable & Rare Diseases Research
Verified
Journal Article
Open access
PDF file
YDYi Deng
Yi Deng
KYKatsuya Yamauchi
Katsuya Yamauchi
PSPeipei Song
Peipei Song
TKTakashi Karako
Takashi Karako
Frailty is an independent risk factor linked to a higher likelihood of various diseases. With limited healthcare resources worldwide — especially in developing countries —the factors that contribute to frailty need to be understood across different populations and a universal model needs to be developed. This could help reduce the burden on healthcare systems and lessen the negative health effects of frailty. This review aims to summarize current evidence on the key factors influencing frailty and its impact on disease outcomes in different countries. The goal is to facilitate the development of strategies that can help prevent or even reverse frailty. Studies were included if they examined physical frailty using validated assessment tools in older adults and explored how various factors affect its development and progression. A comprehensive search of the PubMed database was conducted from March 1 to March 31, 2024 using the keywords "vulnerability" and "influencing factors." Studies published between January 1, 2001, and March 31, 2025 were considered. A total of 1,614 articles were initially identified, with 50 studies ultimately meeting the predefined inclusion and exclusion criteria. The findings indicate that frailty is influenced by a wide range of interrelated risk and protective factors, which in turn have various effects on different disease outcomes. These interconnected factors highlight both the complexity and the potential for targeted intervention. The review provides a comprehensive understanding of the factors associated with frailty in older adults across diverse settings and underscores the urgent need to develop a robust, evidence-based frailty model to facilitate the early identification, prevention, and possibly reversal of frailty.

30 April 2025 in Drug Discoveries & Therapeutics
Verified
Journal Article
Open access
PDF file
YMYa-Nan Ma
Ya-Nan Ma
KKKenji Karako
Kenji Karako
PSPeipei Song
Peipei Song
YXYing Xia
Ying Xia
Herpes Zoster (HZ), caused by the reactivation of the varicella-zoster virus (VZV), is a common infectious disease. Recent studies suggest a potential association between HZ and the development of dementia, particularly Alzheimer's disease and other neurodegenerative disorders. Epidemiological evidence indicates that HZ infection, especially in individuals with central nervous system involvement, may increase the risk of dementia. Pathologically, VZV may contribute to neuronal dysfunction and degeneration by inducing chronic neuroinflammation, infection-related cerebrovascular lesions, and direct central nervous system toxicity. HZ vaccines, particularly novel recombinant subunit vaccines (e.g., Shingrix), not only effectively prevent HZ but may also confer cognitive protection through mechanisms such as "trained immunity" activation and anti-inflammatory response modulation. Multiple natural experiments and retrospective cohort studies have found that HZ vaccination is significantly associated with a reduced risk of dementia, with particularly pronounced protective effects in women and older adults. Although most evidence currently stems from observational studies and is subject to potential confounding factors, the biological plausibility and consistent findings support the potential of HZ vaccination as an adjunctive strategy for dementia prevention. Future prospective randomized controlled trials are needed to further clarify the causal relationship and underlying neuroimmune mechanisms, providing a stronger evidence base for establishing scientific vaccination strategies for older adults and dementia prevention systems.

31 May 2025 in Intractable & Rare Diseases Research
Verified
Journal Article
Open access
PDF file
YLYuanzheng Liu
Yuanzheng Liu
YRYanming Ren
Yanming Ren
PSPeipei Song
Peipei Song
Rare diseases have become a global public health challenge due to their low prevalence, difficult diagnosis, and limited treatment options. Intractable diseases are more common but often involve complex mechanisms, treatment with limited efficacy, and high medical costs, placing a heavy burden on patients and healthcare systems. In recent years, traditional Chinese medicine (TCM) has demonstrated unique advantages in the treatment of intractable and rare diseases and has gradually become an important complementary treatment. The current work is a systematic review of the progress of clinical and experimental research on TCM in typical rare diseases such as amyotrophic lateral sclerosis (ALS), systemic lupus erythematosus (SLE), mitochondrial encephalomyopathy, aplastic anemia (AA), and Wilson's disease (WD). It focuses on the multi-target therapeutic mechanisms of key Chinese herbal compound formulas, including immune regulation, antioxidative stress, and neuroprotection. The core TCM theories of "syndrome differentiation", "different treatments for the same disease" and the "same treatment for different diseases" are also discussed in the context of personalized medicine. In recent years, China has continuously promoted the development of TCM through a series of national plans and supportive policies, such as the 14th Five-Year Plan for TCM development, funding for key special projects, expedited approval pathways, and expanded coverage by medical insurance. These efforts have provided strong support for the clinical translation of TCM and technological innovation in the field of intractable and rare diseases. Notwithstanding the encouraging advances, the field of Chinese medicine continues to grapple with numerous challenges. In the future, the enhancement of mechanistic studies and quality multicenter clinical trials needs to be promoted while further enhancing policy support and international collaboration to substantiate the scientific basis and clinical value of TCM in the prevention and treatment of intractable and rare diseases.

25 February 2026 in Global Health & Medicine
Verified
Journal Article
Open access
PDF file
MUMachiko Uenishi
Machiko Uenishi
PSPeipei Song
Peipei Song
TKTakashi Karako
Takashi Karako
Japan's rapidly aging population presents significant demographic pressures, and yet the country maintains high standards of healthcare delivery with remarkably low rates of preventable and treatable mortality. According to the latest data from the Organization for Economic Co-operation and Development (OECD), Japan ranks 36th among 38 countries in physician density (2.6 per 1,000 population), and yet it records 12.1 physician consultations per person per year–among the highest in the OECD. This article analyzes this paradoxical situation–where high medical performance is maintained despite relatively few physicians–by examining both institutional strengths and emerging vulnerabilities. The strengths include universal health insurance with high public funding; a resource-intensive medical infrastructure; and a robust support network of allied healthcare professionals. Simultaneously, we identify the following vulnerabilities: increasing demand intensity; shortages and an uneven distribution of physicians; hospital financial losses; the limitations of effective gatekeeping under free access systems; and the amplified workload resulting from the concentration of authority and responsibility among physicians. Moreover, we examine initiatives needed to ensure the sustainability of insurance-based healthcare, including: redesigning supply-demand planning and education policies; expanding task sharing and securing funding sources; designing incentives for essential and regional healthcare services; and restructuring access models to value-based utilization and need-based care.

30 April 2026 in BioScience Trends
Verified
Journal Article
Open access
PDF file
YDYi Deng
Yi Deng
KKKenji Karako
Kenji Karako
KYKatsuya Yamauchi
Katsuya Yamauchi
PSPeipei Song
Peipei Song
Frailty has become a pressing health concern in Japan as it has entered a super-aged society. Early identification of frailty is essential to preventing disability, hospitalization, and dependency on long-term care, and yet the implementation of standardized screening across clinical settings remains inconsistent. This review synthesizes current evidence on frailty assessment practices in Japan, highlights key challenges in routine implementation, and examines the potential of emerging digital tools. The feasibility of recent digital innovations — including artificial intelligence analysis of home electricity data, wearable-based mobility monitoring, and EMR-integrated frailty indices — has been demonstrated in pilot settings, though evidence of their large-scale clinical effectiveness remains limited. International comparisons have revealed that countries and regions such as the United Kingdom, Canada, Australia, and Singapore are increasingly implementing electronic frailty indices with policy-level support, offering valuable insights for Japan. Overall, although Japan has made significant progress in recognizing the importance of frailty assessment, substantial gaps remain in standardization, system integration, and clinical implementation. Strengthening national policy frameworks, enhancing workforce training, and accelerating a digital transformation may enable the development of a more comprehensive and scalable frailty-screening system to support healthy aging.

31 August 2025 in Intractable & Rare Diseases Research
Verified
Journal Article
Open access
PDF file
QSQi Sun
Qi Sun
ZJZhixian Jiang
Zhixian Jiang
LYLichao Yang
Lichao Yang
HLHao Liu
Hao Liu
PSPeipei Song
Peipei Song
LYLianwen Yuan
Lianwen Yuan
This systematic review compares inflammatory bowel disease (IBD) management between China and Japan across epidemiology, clinical strategies, health insurance, and social security policies. Epidemiologically, the incidence of IBD is rapidly increasing in China, contributing to a growing disease burden. In contrast, Japan has a stabilized incidence but a rising prevalence, driven by an aging patient population. Clinically, step-up therapy remains the mainstream approach in China, limited by regional and financial disparities in biologic access. In contrast, Japan, benefiting from the "Designated Intractable Diseases" program, favors early intensive therapy with a focus on mucosal healing. In the area of precision medicine, China is advancing rapidly in therapeutic drug monitoring (TDM) for anti-TNF agents. In contrast, Japan leads in AI-assisted endoscopic assessment, despite slower adoption of TDM. Japan's comprehensive insurance covers most costs of IBD; China has significantly reduced drug prices via national negotiations, and yet reimbursement rates vary regionally. China has made progress in telemedicine and standardized fecal microbiota transplantation (FMT); Japan excels in AI endoscopy and use of an elemental diet. To optimize IBD care in the Asia-Pacific, China should enhance access to advanced therapies, implement hierarchical diagnosis/treatment, and develop multi-tiered insurance. Japan must address aging-related challenges and insurance sustainability while expanding use of TDM. Sino-Japanese collaboration in genetics, microbiome research, and AI-driven diagnostics, supported by sustained policy dialogue, is key to advancing precision IBD care and shaping a scalable "Asian model" for chronic disease management.